
“I think it’s really important that people keep signing up to these type of trials to push research forward.”
This trial looked at combining carfilzomib with cyclophosphamide and dexamethasone to treat myeloma.
It was open to people with myeloma that continued to grow during treatment or came back after treatment.
Conclusion
The trial team concluded that continuing with carfilzomib increased the length of time people lived and had no sign of their myeloma after their initial treatment.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed) but may not have been published in a medical journal. The figures we quote above were provided by the research team. We have not analysed the data ourselves.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Kwee Yong
Leeds Institute of Clinical Trials Research (University of Leeds)
Myeloma UK
Onyx Pharmaceuticals, a subsidiary of Amgen Inc
Institute of Cancer Research (ICR)
Haematological Malignancies Diagnostic Service (HMDS)
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
UK Myeloma Research Alliance
Freephone 0808 800 4040
“I think it’s really important that people keep signing up to these type of trials to push research forward.”